Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. May 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
May 2011
Authors
Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • The total annual loss for the 3.7 million people in the U.S. who are visually impaired or blind is estimated at more than 209,000 quality-adjusted life-years.  
  • Visual impairment and blindness cause an annual health utility loss of approximately $10.5 billion. This figure measures lost quality of life when a disease has little or no short-term impact…  
  • Proportion of People with Diabetes with Diabetic Retinopathy of Any Severity, by Country
    Map figures are for both Type 1 and Type 2 diabetes.  
  • In 2015, an estimated 1 million Americans were legally blind.
     
  • An estimated 51,593 Americans ages 40-49 are blind. That grows to 86,623 at ages 75-79 and just under 1 million for ages 80+.